Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial
Year: 2025
Type: article
Language: en
Topic: Lung Cancer Treatments and Mutations
Authors and affiliations:
raw_author_name: Myung-Ju Ahn
raw_affiliation_strings: Samsung Medical Center Sungkyunkwan University School of Medicine
Division of Hematology, Oncology Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea
raw_author_name: Angelo Delmonte
raw_affiliation_strings: IRCCS Istituto Romagnolo per lo Studio dei Tumori - “Dino Amadori”
Medical Oncology Division, IRCCS Istituto Romagnolo per lo Studio dei Tumori - "Dino Amadori", Meldola, Italy
raw_author_name: Sharmistha Ghosh
raw_affiliation_strings: Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond
Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, GBR London, UK
raw_author_name: Maximilian Hochmair
raw_affiliation_strings: Karl Landsteiner Institute of Lung Research and Pulmonary Oncology
Klinik Floridsdorf
Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna, Austria
raw_author_name: Tsung-Ying Yang
raw_affiliation_strings: Taichung Veterans General Hospital
Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
raw_author_name: James Chih-Hsin Yang
raw_affiliation_strings: National Taiwan University Hospital and National Taiwan University Cancer Center
Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan
raw_author_name: Ji-Youn Han
raw_affiliation_strings: National Cancer Center
Department of Hematology and Oncology, National Cancer Center, Goyang, South Korea
raw_author_name: Karin Holmskov Hansen
raw_affiliation_strings: Odense University Hospital
Department of Oncology, Odense University Hospital, Odense, Denmark
raw_author_name: Yanyu Wu
raw_affiliation_strings: Takeda Development Center Americas
Global Evidence and Outcomes - Oncology, Takeda Development Center Americas, Lexington, MA, USA
raw_author_name: Yin Wan
raw_affiliation_strings: Takeda Development Center Americas
Global Evidence and Outcomes - Oncology, Takeda Development Center Americas, Lexington, MA, USA
raw_author_name: Huamao Mark Lin
raw_affiliation_strings: Takeda Development Center Americas
Global Evidence and Outcomes - Oncology, Takeda Development Center Americas, Lexington, MA, USA
raw_author_name: Julian Kretz
raw_affiliation_strings: Takeda Pharmaceuticals International AG
Medical Affairs Oncology, Takeda Pharmaceuticals International AG, Zurich, Switzerland
raw_author_name: Bradley Hupf
raw_affiliation_strings: Takeda Development Center Americas
Oncology Statistics, Takeda Development Center Americas, Lexington, MA, USA
raw_author_name: Ahmet Melih Kurec
raw_affiliation_strings: Takeda Pharmaceutical International
Takeda Pharmaceutical International, Singapore, Singapore
raw_author_name: Eric N. Churchill
raw_affiliation_strings: Takeda Pharmaceuticals
Global Medical Affairs Oncology, Takeda Pharmaceuticals, Lexington, MA, USA
raw_author_name: Robert J. Fram
raw_affiliation_strings: Takeda Development Center Americas
Clinical Science, Takeda Development Center Americas, Lexington, MA, USA
raw_author_name: Citadel Jungco Cabasag
raw_affiliation_strings: IQVIA RDS
Real World Solutions, IQVIA RDS, Courbevoie, France
raw_author_name: Vishal Goriya
raw_affiliation_strings: IQVIA RDS
Real World Solutions, IQVIA RDS, Thane, India
raw_author_name: Yuzhe Zhao
raw_affiliation_strings: IQVIA RDS
IQVIA RDS, Shanghai, China
raw_author_name: Maria Rosario García Campelo
raw_affiliation_strings: University Hospital A Coruña, and Biomedical Research Institute